Phigenix has entered into an agreement with JP Morgan Life Sciences who will assist with the company's financial and regulatory needs, as well as guide its future expansion goals. JP Morgan offers services that focus on solutions for life sciences companies at all stages—from startups to established businesses, pre-clinical through commercialization with decades of experience in the sector while understanding the complex financial and regulatory challenges companies face. Dr. Carlton D. Donald, President and CEO of PHIGENIX commented, “This is a major step for Phigenix as we have reached an inflection point. Partnering with JP Morgan and gaining access to their wealth of expertise and insights will no doubt serve as an invaluable asset for Phigenix’s innovation and growth”.